According to an international study funded by the European Society of Human Reproduction and Embryology, the genetic screening of fertilized eggs for embryo selection during assisted reproduction does not make any difference to live birth rates.
23andMe declared an investment of $300 million on Wednesday, made by GlaxoSmithKline to attain special access to their DNA database.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.